As is characteristic of many studies of this nature, the present preclinical study was limited by the need for the inclusion of more clinicopathological features of PCa, such as the Gleason grade, AR score, volume of metastatic disease, microsatellite instability (MSI) score, tumor mutation burden (TMB), and RAF1/BRAF status. The gene discussed is BRAF; the disease is posterior cortical atrophy.